Market Samachar
CNBC
·
GLOBAL
·
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial - cnbc.com
As reported by CNBC
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
▸ MARKET SAMACHAR VIEW
NEUTRAL
Read full article on CNBC ↗
Market Samachar is a news aggregator. This article was originally published by
CNBC. Tap the button above to read the full story on their site.
🔥 Hot Now
Top stories across markets in the last hour
More from Market Samachar